Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
Hummingbird uses VISTA buzz to secure $290M pact for tumor drug
Hummingbird could one day feather its nest with up to $290 million if its decision to license a phase 2-ready cancer drug to Percheron pays off.
James Waldron
Jun 26, 2025 4:53am
Pfizer CEO makes case for $6B bet on 'fabulous' bispecific
Jun 10, 2025 9:56am
BMS inks $11B biobucks BioNTech deal to join bispecific rush
Jun 2, 2025 8:59am
Immutep's LAG-3 agent posts 'impressive' survival data
May 5, 2025 10:37am
Pfizer ties PD-1 drug to 32% cancer risk reduction in phase 3
Apr 28, 2025 7:25am
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
